Pike M C, Henderson B E, Krailo M D, Duke A, Roy S
Lancet. 1983 Oct 22;2(8356):926-30. doi: 10.1016/s0140-6736(83)90450-6.
A case-control study of 314 breast cancer patients aged less than 37 at diagnosis and 314 individually matched controls was done to assess the influence of oral-contraceptive (OC) use on the risk of the disease. Long-term use before age 25 of combination-type OCs with a "high" content of the progestogen component was associated with increased risk of breast cancer: the relative risk was approximately 4 after 5 years of such use, and 9 cases and no controls had used such combination-type OCs for more than 6 years before age 25. Use of combination-type OCs with a "low" progestogen component appears to increase breast-cancer risk little or not at all.
一项病例对照研究纳入了314例诊断时年龄小于37岁的乳腺癌患者以及314例个体匹配的对照,以评估口服避孕药(OC)的使用对该病风险的影响。25岁前长期使用孕激素成分含量“高”的复方口服避孕药与乳腺癌风险增加相关:使用此类避孕药5年后相对风险约为4,且有9例患者在25岁前使用此类复方口服避孕药超过6年,而对照组无此情况。使用孕激素成分“低”的复方口服避孕药似乎对乳腺癌风险几乎没有增加或根本没有增加。